HUMAW
Humacyte IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-3.16
Beta
2.10
52W High
$0.65
52W Low
$0.08
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Humacyte Inc
Humacyte Inc. is a pioneering biotechnology company focused on the development and commercialization of universally implantable human tissues, notably its innovative human acellular vessel (HAV) technology. By addressing critical challenges in vascular and regenerative medicine, Humacyte differentiates itself through advanced manufacturing capabilities and strong clinical trial advancements. The company's commitment to improving patient outcomes positions it well for strategic partnerships and growth within the regenerative medicine sector. Humacyte's transformative solutions are poised to significantly impact the healthcare landscape by meeting urgent medical needs with novel tissue-based products.
Fundamentals
| Revenue (TTM) | $2.04M |
| Gross Profit (TTM) | $-76.37M |
| EBITDA | $-100.09M |
| Operating Margin | -6603.00% |
| Return on Equity | -249.80% |
| Return on Assets | -52.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.02 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 248.50% |
| Shares Outstanding | 0 |
| Float | $190.86M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/8/2026